| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Ionis Pharmaceuticals, Inc. (IONS) has 19 insiders with recent SEC Form 4 filings, including 0 buys and 15 sells. IONS is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Dir | 156.0K | $8.64M | - | |
| CEO | 99.9K | $5.53M | - | |
| CFO | 82.7K | $4.58M | - | |
| VP | 74.4K | $4.12M | - | |
| VP | 69.7K | $3.86M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2025 | Baroldi Joseph53 | EVP, Chief Business Officer | Sale+OE | 11,950 | $62.16 | $742,838.29 | -27.2% | +26.6% | - | |
| Sep 9, 2025 | O'Neil Patrick R.57 | EVP CLO &General Counsel | Sale+OE | 21,000 | $64.56 | $1,355,661.30 | -15.5% | +26.6% | - | |
| Sep 5, 2025 | Bennett C Frank64 | EVP, Chief Scientific Officer | Sell | 6,000 | $59.60 | $357,580.80 | -6.8% | +33.6% | - | |
| Sep 5, 2025 | Baroldi Joseph53 | EVP, Chief Business Officer | Sale+OE | 250 | $62.00 | $15,500.00 | -0.8% | +33.6% | - | |
| Sep 3, 2025 | Klein Joseph III60 | Director | Sale+OE | 28,000 | $60.00 | $1,680,000.00 | -100% | +34.4% | - | |
| Sep 3, 2025 | Baroldi Joseph53 | EVP, Chief Business Officer | Sale+OE | 32,800 | $59.34 | $1,946,220.28 | -40.2% | +34.4% | - | |
| Sep 3, 2025 | Monia Brett P60 | Chief Executive Officer | Sale+OE | 203,814 | $60.32 | $12,294,703.00 | -24.5% | +34.4% | - | |
| Sep 3, 2025 | Devers Shannon L. | EVP, Chief Human Resources Ofc | Sale+OE | 3,162 | $61.02 | $192,942.71 | -17.4% | +34.4% | - | |
| Sep 3, 2025 | Loscalzo Joseph | Director | Sale+OE | 16,000 | $60.15 | $962,371.20 | -30.6% | +34.4% | - | |
| Sep 3, 2025 | Schneider Eugene64 | EVP, Chf Clinical Develop Ofcr | Sale+OE | 19,658 | $60.81 | $1,195,420.87 | -15.1% | +34.4% | - |